Ibrutinib Differentially Interferes With Surface IgM and IgD BCR Signaling Kinetics In Chronic Lymphocytic Leukemia
Hacken E, Scielzo C, Wierda W et al.
Key Points:
Analysis of BCR signaling activation kinetics following sIgM or sIgD stimulation in CLL cells.
B cells isolated from CLL patients and stimulated with either soluble anti-IgM or anti-IgD and level of HS1 activating tyrosine (Y)397 phosphorylation analyzed.
Ibrutinib affects BCR signaling activation kinetics.
Implications:
sIgM stimulation of CLL cells promotes protracted activation of BCR signaling.
Effect can be inhibited by ibrutinib.
View the original abstract on the ASH website.
